Johnson & Johnson (JNJ)
NYSE: JNJHealthcareDrug Manufacturers - GeneralUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 258.25 -0.08%
JNJ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $622.84B
- P/E (TTM)
- 29.95
- Forward P/E
- 21.36
- EPS (TTM)
- $8.63
- Dividend yield
- 2.03% ($5.24)
- Ex-dividend date
- Aug 25, 2026
- 52-week range
- 184.66 – 281.07
- Day range
- 255.73 – 260.68
- Volume / Avg
- 5.27M / 7.04M
- Beta
- —
- Shares outstanding
- 2.41B
- Next earnings
- Oct 13, 2026
52-week range
JNJ stock today
Shares of Johnson & Johnson (JNJ) finished higher on Oct 7 at $258.45, a gain of 1.44% or $3.67 per share, versus the S&P 500's 0.22% decline. At this level, JNJ sits in the middle of its 52-week range of $184.66 to $281.07: 8.0% below the high, set on Sep 2, 2026 and 40.0% above the low. JNJ is up 25.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 37.3%.
At 29.9x trailing earnings, Johnson & Johnson trades above the peer-group median of 25.7x. Its forward P/E of 21.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 13 before the market opens; analysts expect EPS of $2.90. Johnson & Johnson pays an annual dividend of $5.24 per share, a 2.03% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Johnson & Johnson
Company profileJohnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Joaquin Duato
- Headquarters
- New Brunswick, NJ
- Employees
- 138,200
- Website
- jnj.com
Financial highlights
Full financialsIn fiscal 2025, Johnson & Johnson generated $94.19 billion in revenue, up 6.0% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $26.80 billion (+90.6% year over year), for a net margin of 28.5% versus a median of 22.4% in the prior 5 years. Gross margin was 67.9% (down from 69.1%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B |
| Growth | +6.05% | +4.30% | +6.46% | +1.59% | -4.65% |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
Analyst forecast
ForecastConsensus (23 analysts)
buy
Avg. price target
$279.64+8.20%
- Strong buy 5
- Buy 11
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 13, 2026
- EPS estimate
- $2.90
- Last reported (Q2 2026)
- Jul 23, 2026
- EPS actual vs est.
- $2.27 vs —
Dividends
Dividend history- Annual dividend
- $5.24
- Dividend yield
- 2.03%
- Last payment
- $1.34
- Ex-dividend date
- Aug 25, 2026
JNJ news
All JNJ news- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXNasdaqHALO, JNJ, ARGX, HOWL
- PFE vs. JNJ: Which Stock Is the Better Value Option?NasdaqPFE, JNJ
- Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?NasdaqJNJ, BSX, MDT, SYK
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationNasdaqJNJ, PFE, NVO, LLY
- 2 Beaten-Down Stocks Worth Buying and Holding for the Next DecadeNasdaqISRG, NFLX, JNJ, MDT
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingNasdaqLLY, AZN, JNJ, ABBV
- Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.NasdaqJNJ, LLY, MDT
- The Stock Market Just Flashed a Warning Signal Seen Only Twice in 155 Years. Here Are 3 Stocks That Can Weather What History Says Comes Next.NasdaqJNJ, PG, EPD
Johnson & Johnson peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ABBVAbbVie Inc. | 271.36 | +1.75% | $479.52B | vs JNJ |
| MRKMerck & Company Inc. | 142.79 | +0.60% | $352.29B | vs JNJ |
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs JNJ |
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs JNJ |
| AMGNAmgen Inc. | 413.08 | +2.60% | $223.32B | vs JNJ |
| GILDGilead Sciences Inc. | 146.85 | +1.82% | $182.09B | vs JNJ |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs JNJ |
| LLYEli Lilly and Company | 1,188.72 | +2.70% | $1.06T | vs JNJ |
Indexes, lists and sector
Index membership
Appears in lists
Johnson & Johnson stock FAQ
What is Johnson & Johnson's stock price today?
JNJ last traded at $258.45 as of Oct 7, 4:00 PM EDT, up 1.44% on the day. Prices are delayed at least 15 minutes.
Does Johnson & Johnson pay a dividend?
Yes. Johnson & Johnson pays $5.24 per share annually, a 2.03% yield. The most recent dividend of $1.34 had an ex-dividend date of Aug 25, 2026.
When is Johnson & Johnson's next earnings date?
Johnson & Johnson is expected to report earnings on Tuesday, October 13, 2026. Analysts expect EPS of $2.90.
What is JNJ's P/E ratio?
JNJ trades at a trailing P/E ratio of 29.95 and a forward P/E of 21.36, compared with a median of 25.7 for its closest peers.
Is Johnson & Johnson in the S&P 500?
Yes. Johnson & Johnson (JNJ) is a constituent of the S&P 500 index.
Who is Johnson & Johnson's CEO?
Mr. Joaquin Duato is the chief executive officer of Johnson & Johnson, which has about 138,200 employees.
Has JNJ ever split its stock?
Yes. The most recent JNJ stock split was a 2-for-1 split on Jun 13, 2001, one of 6 splits on record.